Cargando…

Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: A case series

This longitudinal cohort study aimed to determine whether circulating neurofilaments (NFs) can monitor response to molecular therapies in newborns with spinal muscular atrophy (SMA; NCT02831296). We applied a mixed-effect model to examine differences in serum NF levels among healthy control infants...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alves, Christiano R.R., Petrillo, Marco, Spellman, Rebecca, Garner, Reid, Zhang, Ren, Kiefer, Michael, Simeone, Sarah, Sohn, Jihee, Eichelberger, Eric J., Rodrigues, Emma, Arruda, Elizabeth A., Townsend, Elise L., Farwell, Wildon, Swoboda, Kathryn J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605296/ https://www.ncbi.nlm.nih.gov/pubmed/34853799 http://dx.doi.org/10.1016/j.omtm.2021.10.011

Ejemplares similares

Increased systemic HSP70B levels in spinal muscular atrophy infants
por: Eichelberger, Eric J., et al.
Publicado: (2021)

Neurofilament as a potential biomarker for spinal muscular atrophy
por: Darras, Basil T., et al.
Publicado: (2019)

Whole‐blood dysregulation of actin‐cytoskeleton pathway in adult spinal muscular atrophy patients
por: Siranosian, Jennifer J., et al.
Publicado: (2020)

Whole blood survival motor neuron protein levels correlate with severity of denervation in spinal muscular atrophy
por: Alves, Christiano R. R., et al.
Publicado: (2020)

Identifying Biomarkers of Spinal Muscular Atrophy for Further Development
por: Glascock, Jacqueline, et al.
Publicado: (2023)

Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States
por: Lally, Cathy, et al.
Publicado: (2017)

Impaired kidney structure and function in spinal muscular atrophy
por: Nery, Flávia C., et al.
Publicado: (2019)

Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study
por: Acsadi, Gyula, et al.
Publicado: (2021)

Spinal Muscular Atrophy (SMA) Subtype Concordance in Siblings: Findings From the Cure SMA Cohort
por: Jones, Cynthia C., et al.
Publicado: (2020)

Circulating neurofilaments to track dorsal root ganglion toxicity risks with AAV-mediated gene therapy
por: Farrar, Michelle A., et al.
Publicado: (2022)

An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials
por: Darras, Basil T., et al.
Publicado: (2019)

The altered expression of neurofilament in mouse models and patients with spinal muscular atrophy
por: Spicer, Charlotte, et al.
Publicado: (2021)

Position Statement: Sharing of Clinical Research Data in Spinal Muscular Atrophy to Accelerate Research and Improve Outcomes for Patients
por: Lochmüller, Hanns, et al.
Publicado: (2018)

Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies
por: Darras, Basil T., et al.
Publicado: (2019)

Base editing as a genetic treatment for spinal muscular atrophy
por: Alves, Christiano R. R., et al.
Publicado: (2023)

Comparative All-Cause Mortality Among a Large Population of Patients with Spinal Muscular Atrophy Versus Matched Controls
por: Viscidi, Emma, et al.
Publicado: (2021)

Nusinersen improves walking distance and reduces fatigue in later‐onset spinal muscular atrophy
por: Montes, Jacqueline, et al.
Publicado: (2019)

Correction to: Comparative All-Cause Mortality Among a Large Population of Patients with Spinal Muscular Atrophy Versus Matched Controls
por: Viscidi, Emma, et al.
Publicado: (2022)

Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children
por: Nitz, Elisa, et al.
Publicado: (2021)

Serum Creatine, Not Neurofilament Light, Is Elevated in CHCHD10-Linked Spinal Muscular Atrophy
por: Järvilehto, Julius, et al.
Publicado: (2022)

Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients
por: Faravelli, Irene, et al.
Publicado: (2020)

Comparison of neurofilament light and heavy chain in spinal muscular atrophy and amyotrophic lateral sclerosis: A pilot study
por: Li, Jin‐Yue, et al.
Publicado: (2023)

Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients
por: Magen, Iddo, et al.
Publicado: (2022)

Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164–76. doi:10.1007/s12325-019-00923-8
por: Sandrock, Alfred W., et al.
Publicado: (2019)

Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
por: De Vivo, Darryl C., et al.
Publicado: (2019)

Emerging therapies and challenges in spinal muscular atrophy
por: Farrar, Michelle A., et al.
Publicado: (2017)

A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen
por: Paris, Alessio, et al.
Publicado: (2022)

Case of Marked Muscular Atrophy of Hands and Fore-Arms—Progressive Muscular Atrophy(?)
por: Ness, R. Barclay
Publicado: (1895)

Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen
por: Totzeck, Andreas, et al.
Publicado: (2019)

Lack of Cholesterol Awareness among Physicians Who Smoke
por: Scranton, Richard E., et al.
Publicado: (2009)

Neurofilament light protein in blood predicts regional atrophy in Huntington disease
por: Johnson, Eileanoir B., et al.
Publicado: (2018)

Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience
por: Haché, Manon, et al.
Publicado: (2016)

Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011)

Progressive Muscular Atrophy
por: Omar, A.
Publicado: (1947)

Progressive Muscular Atrophy
por: Omar, A.
Publicado: (1947)

Progressive Muscular Atrophy
por: Omer, M. A.
Publicado: (1949)

Muscular Atrophy and Sclerodermia
por: Nixon, J. A.
Publicado: (1903)

Progressive Muscular Atrophy
Publicado: (1874)

Muscular Atrophy and Sclerodermia
Publicado: (1904)

Acute Muscular Atrophy
por: Haddon, John
Publicado: (1870)

Cannot write session to /tmp/vufind_sessions/sess_mt6i1fj0ppge7sik75rti4juh5